Gene Fusion Characterization of Rare Aggressive Prostate Cancer Variants - Adenosquamous Carcinoma, Pleomorphic Giant Cell Carcinoma, and Sarcomatoid Carcinoma: An Analysis of 19 Cases by Alhamar, Mohamed et al.
Henry Ford Health System 
Henry Ford Health System Scholarly Commons 
Pathology Articles Pathology 
7-8-2020 
Gene Fusion Characterization of Rare Aggressive Prostate Cancer 
Variants - Adenosquamous Carcinoma, Pleomorphic Giant Cell 
Carcinoma, and Sarcomatoid Carcinoma: An Analysis of 19 Cases 
Mohamed Alhamar 
Tudor Vladislav 
Steven C. Smith 
Yuan Gao 
Liang Cheng 
See next page for additional authors 
Follow this and additional works at: https://scholarlycommons.henryford.com/pathology_articles 
Authors 
Mohamed Alhamar, Tudor Vladislav, Steven C. Smith, Yuan Gao, Liang Cheng, Laura A. Favazza, Ali M. 
Alani, Michael M. Ittmann, Nicole D. Riddle, Lisa J. Whiteley, Nilesh S. Gupta, Shannon Carskadon, Juan C. 
Gomez-Gelvez, Dhananjay A. Chitale, Nallasivam Palanisamy, Ondrej Hes, Kiril Trpkov, and Sean R. 
Williamson 
This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process, which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1111/HIS.14205
 This article is protected by copyright. All rights reserved
DR STEVEN CHRISTOPHER SMITH (Orcid ID : 0000-0003-0982-4607)
PROFESSOR LIANG  CHENG (Orcid ID : 0000-0002-6801-5140)
DR NALLASIVAM  PALANISAMY (Orcid ID : 0000-0002-0633-9772)
DR KIRIL  TRPKOV (Orcid ID : 0000-0003-3142-8846)
DR SEAN R WILLIAMSON (Orcid ID : 0000-0002-3898-1460)
Article type      : Original Article
Gene Fusion Characterization of Rare Aggressive Prostate Cancer Variants - Adenosquamous 
Carcinoma, Pleomorphic Giant Cell Carcinoma, and Sarcomatoid Carcinoma: An Analysis of 19 
Cases
Mohamed Alhamar, MD, 1 I. Tudor Vladislav, MD, 1 Steven C. Smith, MD, PhD, 2 Yuan Gao, MD, 3 Liang 
Cheng, MD, 4 Laura A. Favazza, DO, 1 Ali M. Alani, MD, 5 Michael M. Ittmann, MD, 5 Nicole D. Riddle, MD, 6 
Lisa J Whiteley, BA, 1 Nilesh S. Gupta, MD, 1 Shannon Carskadon, MS, 7 Juan C Gomez-Gelvez, MD, 1 
Dhananjay A. Chitale, MD, PhD, 1,8 Nallasivam Palanisamy, PhD, 7 Ondrej Hes, MD, PhD, 9 Kiril Trpkov, MD, 
10 Sean R. Williamson, MD 1,8
1. Department of Pathology and Laboratory Medicine and Henry Ford Cancer Institute, Henry 
Ford Health System, Detroit, MI, USA; 
2. Department of Pathology, Virginia Commonwealth University, Richmond, Virginia, USA; 
3. Department of Pathology, Memorial University, St. John's, Newfoundland, Canada;A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
4. Department of Pathology, Indiana University School of Medicine, Indianapolis, Indiana, USA;
5. Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX, USA;
6. Department of Pathology, Ruffolo, Hooper, and Associates, USF Health, Tampa, FL
7. Department of Urology, Vattikutti Urology Institute, Henry Ford Health System, Detroit, MI, 
USA;
8. Department of Pathology, Wayne State University School of Medicine, Detroit, MI, USA;
9. Department of Pathology, Charles University Faculty of Medicine, Plzen, Czech Republic;
10. Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University 
of   Calgary, Calgary, Alberta, Canada;
*This work was presented, in part, at the United States and Canadian Academy of Pathology (USCAP) Annual 
Meeting, 2019. 
Address correspondence and reprint requests to (current address): 
Sean R. Williamson, MD 
Cleveland Clinic 
9500 Euclid Ave (L25)
Cleveland, OH, 44195
Email: williamson.sean@outlook.com  
Phone: 216-445-4896
Fax: 216-445-3707
Conflicts of Interest and Source of Funding: Supported in part by Henry Ford Health System internal funding 
to SRW. A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
Running head: Rare Aggressive Prostate Cancer Variants
Keywords: prostate cancer; adenosquamous carcinoma; pleomorphic giant cell carcinoma; sarcomatoid 
carcinoma; BRAF; ERG; GRHL2; FAM131A; SND1;
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
Abstract 
Aims: We evaluated the molecular underpinnings of rare aggressive prostate cancer variants adenosquamous, 
pleomorphic giant cell, and sarcomatoid carcinomas. 
Methods and Results: We retrieved 19 tumors with one or more variant(s) and performed ERG 
immunohistochemistry, a next-generation sequencing assay targeting recurrent gene fusions, and 
fluorescence in situ hybridization (FISH) for ERG and BRAF. Divergent differentiation included: sarcomatoid 
(n=10), adenosquamous (n=7), and pleomorphic giant cell carcinoma (n=7). Five patients had more than one 
variant. Four had variants only in metastases. ERG rearrangement was detected in 9 (47%, 7 via sequencing, 
showing TMPRSS2-ERG and one GRHL2-ERG fusion, and 2 via FISH, showing rearrangement via deletion). Of 
these, ERG immunohistochemistry was positive in the adenocarcinoma for 8/9 (89%) but only 5/9 (56%, 
typically decreased) in the variant. One patient had false-positive ERG immunohistochemistry in the 
sarcomatoid component despite negative FISH. Two (11%) harbored BRAF fusions (FAM131A-BRAF and SND1-
BRAF). 
Conclusions: ERG gene fusions are present in these rare prostate cancer variants with a close frequency to 
conventional prostate cancer (9/19, 47%). ERG immunohistochemistry usually detects rearrangement in the 
adenocarcinoma but is less sensitive for the variant histology with weak to negative staining.   
Adenosquamous and sarcomatoid variants particularly can occur together. Molecular assessment may be an 
additional tool in select cases to confirm prostatic origin of unusual tumors. The presence of 2 BRAF gene 
rearrangements suggests that this gene fusion may be enriched in this setting, as RAF kinase fusions have 
been previously reported in 1-2% of prostate cancers. 
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Introduction: 
The overwhelming majority of prostate cancer is conventional acinar adenocarcinoma.  Although 
architectural and cytological variations are common, such as atrophic, pseudohyperplastic, or foamy gland 
variants, unusual histological variants such as adenosquamous carcinoma, sarcomatoid carcinoma, 
pleomorphic giant cell carcinoma are exceedingly rare and are known to behave aggressively. (1, 2) 
Approximately half of adenosquamous and sarcomatoid carcinomas have been reported in the setting of 
previous treatment for conventional prostatic adenocarcinoma, suggesting evolution from the conventional 
carcinoma component. (3) However, understanding of the molecular characteristics of these rare variants is 
currently scant. To our knowledge, only a few publications assessing a handful of cases have examined the 
molecular characteristics of these rare variants. (4-7) Better understanding of the molecular features of these 
tumor variants could shed light on the clinical and biologic diversity of prostate cancer and potentially have 
therapeutic significance. We studied a cohort of rare prostatic carcinoma variants including adenosquamous 
carcinoma, sarcomatoid carcinoma, pleomorphic giant cell carcinoma for their molecular profiles, using 
fluorescence in situ hybridization and next generation sequencing.
Materials and methods:
Following institutional review board approval from the Henry Ford Health System, we retrieved tumors from 
19 patients with rare prostatic carcinoma variants including adenosquamous carcinoma, sarcomatoid 
carcinoma, pleomorphic giant cell carcinoma or a combination of more than one of these, from the pathology 
archives of the participating institutions, from 2013 to 2019. Patients in whom a diagnosis of urothelial 
carcinoma could not be disproven were excluded from the cohort, using selective immunohistochemistry for 
prostate-specific antigen, prostate specific acid phosphatase, prostein, and NKX3.1. Antibodies against p63 
and high molecular weight cytokeratin were used to support squamous differentiation in selected cases and 
as applicable to argue against urothelial carcinoma. Hematoxylin and eosin stained slides and 
immunohistochemistry slides were reviewed by two of the authors (MA & SRW). The final cohort included a 
total of 19 patients with prostate cancer showing one or more of these variants found either within the 
prostate (15 patients) or in a metastatic lesion (4 patients). ERG immunohistochemistry was performed on 17 
tumors with sufficient material using anti-human ERG antibody clone EP111 (Dako, Carpinteria, CA) in a Dako 
automated instrument. 
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Fluorescence in situ hybridization: 
Fluorescence in situ hybridization analysis for ERG and BRAF genes were performed using bacterial artificial 
chromosome derived break-apart probes, using methods described previously. (8, 9) ERG fluorescence in situ 
hybridization was performed on 12 specimens and (after finding unexpected BRAF fusions in 2 index cases 
using the sequencing assay) BRAF fluorescence in situ hybridization was tested in 15 tumors (Table 1). 
Fluorescence in situ hybridization results were reviewed by four of the authors (MA, NP, SC, & SRW).
Next generation sequencing:
A multiplex RNA fusion panel (Archer® FusionPlex® Solid Tumor Kit) was performed on RNA extracted from 
representative formalin-fixed, paraffin-embedded tissue tumor blocks. Tissue sections were marked for the 
areas of variant histology and macro-dissected from the slide, if not already pure by histologic review. Briefly, 
this assay is a targeted sequencing assay that uses anchored multiplex polymerase chain reaction to prepare 
target-enriched cDNA libraries from RNA to detect fusions and other mutations in over 50 genes linked to 
known solid tumors, using methods previously described. (10) Genes targeted in this assay include: AKT3, 
ALK, ARHGAP26, AXL, BRAF (fusion and V600E mutation), BRD3, BRD4, EGFR (fusion and mutation), ERG, 
ESR1, ETV1, ETV4, ETV5, ETV6, EWSR1, FGFR1, FGFR2, FGFR3, FGR, INSR, MAML2, MAST1, MAST2, MET 
(fusion and mutation), MSMB, MUSK, MYB, NOTCH1, NOTCH2, NRG1, NTRK1, NTRK2, NTRK3, NUMBL, 
NUTM1, PDGFRA (fusion and mutation), PDGFRB, PIK3CA, PKN1, PPARG, PRKCA, PRKCB, RAF1, RELA, RET, 
ROS1, RSPO2, RSPO3, TERT, TFE3, TFE3, TFEB, THADA, and TMPRSS2.  Seventeen formalin-fixed, paraffin-
embedded tissue blocks of different tumors were tested via this method, four of which failed quality metrics, 
whereas the remaining 13 tumors were informative and yielded positive or negative results. Sequencing 
results were reviewed by three molecular pathologists (JCGG, LAF, & DAC) and two of the authors (MA & 
SRW).
Results:
A total of 19 patients were analyzed (Table 1) and revealed the following; prostate carcinoma with 
sarcomatoid (n=10), adenosquamous (n=7, Figure 1), and pleomorphic giant cell carcinoma (n=7, Figure 2) 
divergent differentiation. Five patients had more than one variant (adenosquamous and sarcomatoid in 4 
patients; and sarcomatoid and pleomorphic giant cell in 1 patient). Divergent differentiation was present only A
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in metastases for 4 patients. These metastatic sites included pelvic lymph node dissections, a perirectal mass 
(likely representing a replaced lymph node), a retroperitoneal mass (also likely representing a lymph node), 
and a bone (femoral head) metastasis.
Molecular characterization:
ERG rearrangement was detected in 9 tumors (47%, 7 via sequencing, showing TMPRSS2-ERG & GRHL2-ERG 
fusions, and 2 via fluorescence in situ hybridization, showing rearrangement via deletion). Of note a GRHL2-
ERG fusion has been previously reported in prostate cancer in an annotation database from the Cancer 
Genome Atlas as TCGA-V1-A9OT, (11) which was noted to be Gleason score 3+3=6 (Grade Group 1) in the 
original pathology report (without mention of any variant histology) and the available whole slide image 
demonstrated a small focus of Gleason score 3+3=6 (Grade Group 1) cancer 
(https://cancer.digitalslidearchive.org/). Two tumors (11%) were detected to harbor BRAF gene fusion by 
sequencing and confirmed by fluorescence in situ hybridization (Figure 3, cases 2 and 4), with fusions being 
FAM131A-BRAF and SND1-BRAF (Table 2). Breakpoints involved exons 10 and 9 of BRAF, respectively, 
consistent with prior reports of retaining the C-terminus tyrosine kinase domain in the fusion. (9) BRAF V600E 
mutation was, however, not detected.
Some of the remaining tumors were incompletely characterized. In 5 specimens, fluorescence in situ 
hybridization was negative for ERG and BRAF rearrangement. The sequencing assay detected no definite 
fusions; however, it did not meet quality control metrics and could not be interpreted as reliable. This 
includes 1 autopsy specimen, in which sequencing could not be performed due to the suboptimal material 
(patient 5). For tumors with sequencing showing TMPRSS2-ERG, confirmatory fluorescence in situ 
hybridization was deemed not necessary, as this is the prototypical fusion described in prostate cancer. 
Confirmatory fluorescence in situ hybridization was attempted in the tumor with GRHL2-ERG fusion, but was 
unsuccessful, possibly related to preanalytical factors, being a metastatic bone specimen. One tumor had 
ERG-positive fluorescence in situ hybridization in the low-grade adenocarcinoma component, but a negative 
fluorescence in situ hybridization was found in the sarcomatoid component, suggesting co-existence of two 
different neoplastic clones.
Three patients had histologically disparate tumors (Figure 4) at different sites (1- adenosquamous carcinoma 
only in the lymph nodes but not the primary tumor, 2- separate adenosquamous and sarcomatoid A
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metastases, and 3- conventional and pleomorphic carcinoma in different metastatic sites). Of these, two were 
confirmed to have the same fusion in both components: case 2 demonstrated the FAM131A-BRAF fusion in 
sequencing of two separate specimens (sarcomatous perirectal mass and adenosquamous carcinoma 
involving lymph nodes). The prostatectomy from this patient, which did not exhibit variant histology, was not 
available for testing. The tumor from patient 1 was confirmed to have ERG rearrangement in both glandular 
and squamous components of lymph node metastases using fluorescence in situ hybridization. The third (case 
4) had conventional adenocarcinoma (single cells and solid growth) with SND-BRAF fusion in a testicular 
metastasis at initial presentation. A retroperitoneal tumor biopsy from the same patient demonstrated 
pleomorphic giant cell carcinoma; however, there was insufficient tissue for molecular testing to verify the 
same fusion in the second site. 
ERG immunohistochemistry 
ERG immunohistochemistry was performed in 17 tumors (Table 3, Figure 5). One patient (patient 1) had ERG 
rearrangement detected via fluorescence in situ hybridization (deletion) but had negative 
immunohistochemistry in both the adenocarcinoma and the variant (false negative). In 5 patients with ERG 
rearrangement, staining was clearly positive in the adenocarcinoma but markedly decreased or negative in 
the variant. In 1 patient, ERG staining was weak in both components, and in another (patient 4), ERG staining 
was negative in the variant tumor but positive in a separate, unrelated low-grade prostatic adenocarcinoma. 
Finally, one tumor which showed negative ERG fluorescence in situ hybridization showed negative 
immunohistochemistry in the adenocarcinoma but variable negative to moderate staining of the sarcomatoid 
component (patient 16). Overall, 8/9 (89%) tumors with confirmed ERG rearrangement had positive staining 
in the associated adenocarcinoma, whereas only 5/9 (56%) had definite positive staining in the variant 
component. 
Discussion: 
Adenosquamous carcinoma, sarcomatoid carcinoma, pleomorphic giant cell carcinoma are extremely rare 
variants of prostate adenocarcinoma that are typically associated with a dismal prognosis. (1, 12-14) A 
substantial fraction of these unusual morphologies are encountered in the post-treatment setting, suggesting 
that they often evolve from usual carcinoma (Table 3). Although the optimal treatment for these variants is 
not yet clarified, likely due to their rarity, it is important to discriminate them from the mimics, especially A
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urothelial carcinoma, due to the markedly different treatment implications of these diagnoses. Additionally, 
the possibility of coexistence of prostatic adenocarcinoma and urothelial carcinoma, or both metastatic to the 
same lymph node, is conceivable and usually requires a robust morphological assessment and a judicious 
immunohistochemistry. 
Previously, only a few studies have evaluated molecular characteristics of these rare variants. Rodrigues et al 
found 3 sarcomatoid prostate cancers to have ERG rearrangement via deletion using fluorescence in situ 
hybridization. (4) Another study reported 2 cases of prostatic adenocarcinoma with squamous 
transformation, which harbored SPOP mutation and PTEN deletion in one and TMPRSS2-ERG fusion and PTEN 
mutation in another. (5) Recently, Lotan et al studied 8 prostatic adenocarcinomas with pleomorphic giant 
cell features and found DNA damage repair mutations but not ERG fusions. (7)
Recurrent gene rearrangements involving ERG or other members of the ETS family of genes occur in 
approximately 50% of prostate adenocarcinoma. (15) From our study, ERG gene fusions appear to be also 
present in these rare prostate cancer variants with a similar frequency to the conventional prostate cancer 
(9/19, 47%). Of note, ERG immunohistochemistry does not demonstrate an ideal correlation with 
rearrangement in these variants, with 8 of 9 rearranged tumors showing positive staining in the prostatic 
adenocarcinoma but only 5 of 9 showing positive staining in the variant, typically with a decreased 
distribution and intensity. We interpret one tumor as showing a false-positive immunohistochemical result in 
the sarcomatoid component, since fluorescence in situ hybridization was negative for rearrangement in this 
case and the admixed adenocarcinoma showed negative immunohistochemistry. Anecdotally, we have 
occasionally encountered weak to moderate ERG immunohistochemical staining in non-vascular spindle cell 
lesions of soft tissue (unpublished observations), which may account for this finding. This is also in keeping 
with the findings of others including occasional ERG immunohistochemical positivity in other mesenchymal 
and spindle cell tumors. (16) 
Interestingly, the presence of BRAF gene rearrangements in two tumors (10% of our cohort) suggests that this 
gene fusion may be enriched in this setting, as RAF kinase fusions have been previously reported in only 1-2% 
of prostate cancers, including from multiple large scale genetic profiling studies as assessed via cbioportal.org. 
(9, 17-21) Additional clinical and molecular studies regarding such fusions will be necessary to better 
understand targeting the RAF kinase pathways as a potential therapy option in these patients. SND1-BRAF 
fusion has been reported in pancreatic acinar cell carcinoma and lung cancer, (22-26) and a fusion similar to A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
FAM131A-BRAF has been described in pilocytic astrocytoma (FAM131B-BRAF). (27, 28).  A new 5’ fusion 
partner of ERG, GRHL2, was identified in one of the tumors (case 18). Although not well characterized at 
present, this fusion is also noted in an additional case in the Cancer Genome Atlas fusion data as case TCGA-
V1-A9OT-01A. (11) GRHL2 is reported to be a coregulator of the androgen receptor, similar to TMPRSS2 and 
other fusion partner genes of ERG. (29) The original pathology report and scanned slide from this case 
demonstrated a Gleason score 3+3=6 (Grade Group 1) prostatic adenocarcinoma, but without variant 
histology. 
Besides the relatively small number of patients, one limitation of our study is that fluorescence in situ 
hybridization and sequencing were performed with assays against known gene fusions. Because a substantial 
fraction of the evaluated tumors (8/19, 42%) yielded negative results, we cannot exclude the presence of 
novel gene fusions. Additional studies using other techniques (e.g. RNA-seq) may be helpful in shedding more 
light on these rare variants of prostate cancer. And as noted recently by Lotan et al, other non-fusion 
molecular mechanisms may be responsible for pathogenesis of some of these tumors. (7) Gene fusions may 
be difficult to target therapeutically, making these findings of limited value for treatment; however, this may 
be of relevance to diagnostic pathology practice, if fluorescence in situ hybridization or molecular studies are 
employed to attempt to confirm the prostatic origin of histologically unusual tumors occurring in the prostate 
or at distant sites after treatment. 
Conclusions:
ERG gene fusions are present in rare prostate cancer variants adenosquamous, sarcomatoid, and pleomorphic 
giant cell carcinomas with a close frequency to conventional prostate cancer (47%).  Adenosquamous and 
sarcomatoid variants in particular can sometimes occur together. Molecular assessment may be an additional 
tool in confirming prostatic origin for tumors with unusual morphology, either occurring in the prostate or at 
distant, metastatic sites in the setting of known prostate cancer. ERG immunohistochemistry is less robust 
than molecular techniques when assessed in the variant components of these tumors. The presence of 2 
BRAF gene rearrangements suggests that this gene fusion may be enriched in this setting, as RAF kinase 
fusions have been previously reported in 1-2% of prostate cancers. Further study will be helpful to determine 
whether therapy targeting BRAF may be of value in patients with rearranged tumors.
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Figure Legends: 
Figure 1:  This adenosquamous prostate cancer shows a transition from adenocarcinoma (top) to squamous 
cell carcinoma (bottom). 
Figure 2: This carcinoma with pleomorphic giant cell features shows a transition from solid adenocarcinoma 
(top) to bizarre giant tumor cells (center and bottom).
Figure 3: Fluorescence in situ hybridization for BRAF in case 4 confirms the sequencing results, showing 
multiple copies of the BRAF probes, with several demonstrating widely separated signals.
Figure 4: Tumor 2 with BRAF rearrangement demonstrated a lymph node metastasis composed partly of 
glandular structures (A). There is partial p63 reactivity in the glandular component (B) and partial positivity for 
NKX3.1 in the adjacent cancer (C), which also showed partial positivity for prostate-specific antigen (D). 
Squamous differentiation was also present in the same lymph node, (E) and sarcomatoid carcinoma was 
present in a separate mass (F). A FAM131A-BRAF gene fusion was demonstrated in both morphologies by 
sequencing.
Figure 5: Tumor 15 with ERG rearrangement shows positive ERG immunohistochemical staining in a large 
gland of the prostatic adenocarcinoma (A, right), but weak to negative staining in the sarcomatoid component 
(A, left). At higher magnification, the sarcomatoid tumor cells vary from negative to weakly positive (B). 
Tumor 16 was interpreted as having false-positive ERG immunohistochemistry. The associated prostatic A
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adenocarcinoma (C) is negative for ERG immunohistochemistry; however, the spindle cell component showed 
a variable reaction, ranging from negative to moderate positivity (D). 
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Patient  
Location of Divergent 
Differentiation  
Type of Divergent 
Differentiation  
Overall 
molecular 
status 
Fluorescence 
in situ 
hybridization 
BRAF 
Fluorescence 
in situ 
hybridization 
ERG 
Next Generation 
Sequencing 
1 Lymph node metastasis Adenosquamous ERG Negative 5’deletion Not done 
2 
Lymph node metastasis and 
perirectal mass 
Adenosquamous & sarcomatoid BRAF Positive Negative 
FAM131A-BRAF 
fusion 
3 Prostate Sarcomatoid Negative Negative Negative 
Quality control 
fail x2 
4 Retroperitoneal metastasis Pleomorphic giant cell BRAF 
Positive + 
aneuploid 
Negative 
SND1-BRAF 
fusion 
5 Prostate/bladder Pleomorphic giant cell Negative Negative Negative Not done 
6 Prostate Sarcomatoid ERG Negative Not done 
TMPRSS2-ERG 
fusion 
7 Prostate Adenosquamous ERG Negative Not done 
TMPRSS2-ERG 
fusion 
8 Prostate  Adenosquamous & sarcomatoid ERG Negative Not done 
TMPRSS2-ERG 
fusion 
9 Prostate/bladder neck  Sarcomatoid  Negative Negative Negative 
Quality control 
fail 
10 Prostate Adenosquamous & sarcomatoid  Negative Negative Negative 
Quality control 
fail 
11 Prostate Pleomorphic giant cell Negative Negative Negative Negative 
12 Prostate Adenosquamous & sarcomatoid ERG Not done Not done 
TMPRSS2-ERG 
fusion 
13 Prostate Sarcomatoid Negative Negative Negative Negative A
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14 Prostate Pleomorphic giant cell Negative Negative Negative Negative 
15 Prostate Pleomorphic giant cell ERG Not done Not done 
TMPRSS2-ERG 
fusion 
16 Prostate Sarcomatoid Negative Negative Negative 
Quality control 
fail 
17 Prostate/bladder neck 
Sarcomatoid & pleomorphic 
giant cell  
ERG Negative  5’ deletion Negative 
18 Femoral head metastasis Adenosquamous ERG Not done Failed 
GRHL2-ERG 
fusion 
19 Prostate Pleomorphic giant cell ERG Not done Not done 
TMPRSS2-ERG 
fusion 
 
Table 1: Types of divergent differentiation and overall molecular status.  
 
 
Fusions Reads (# / %) Start Sites Segments 
GRHL2 (exon 4) ERG (exon 2) 111 / 75 58 GRHL2(+) chr8:102570812→102571040 
 ERG(-)     chr21:39817544→39817327 
FAMA1A (exon 1) BRAF (exon 10) 41 / 42 17 FAM131A(+) chr3:184053800→184053911 
BRAF(-)        chr7:140482957→140482930 
SND1 (exon 10) BRAF (exon 9) 308 / 83 63 SND1(+) chr7:127361341→127361454 
BRAF(-)  chr7:140487384→140487348 
 
Table 2: Molecular characteristics of the unique fusions in the cohort. 
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Patient Age 
Type of 
Divergent 
Differentiation 
Prior treatment 
Overall 
molecular 
status 
ERG IHC- 
adenocarcinoma 
ERG IHC - variant 
1 63 Adenosquamous No ERG Negative Negative 
2 68 
Adenosquamous 
& sarcomatoid 
ADT BRAF Negative Negative 
3 77 Sarcomatoid No Negative Negative* Negative 
4 55 
Pleomorphic 
giant cell 
No BRAF Negative Negative 
5 91 
Pleomorphic 
giant cell 
ADT and radiation Negative Negative Negative 
6 77 Sarcomatoid Radiation ERG Positive Negative 
7 77 Adenosquamous ADT ERG Weak Weak 
8 58 
Adenosquamous 
& sarcomatoid 
ADT (short interval from diagnosis) ERG Positive Focal 
9 86 Sarcomatoid Radiation Negative Negative Negative 
10 71 
Adenosquamous 
& sarcomatoid 
Radiation Negative 
  
11 76 
Pleomorphic 
giant cell 
ADT Negative 
  
12 67 
Adenosquamous 
& sarcomatoid 
ADT ERG Positive 
Negative / 
equivocal 
13 86 Sarcomatoid No Negative Negative Negative 
14 67 
Pleomorphic 
giant cell 
ADT Negative Negative Negative 
15 78 
Pleomorphic 
giant cell 
Likely** ERG Positive Focal weak 
16 67 Sarcomatoid Brachytherapy Negative Negative 
Variable negative 
to moderate 
17 90 
Sarcomatoid & 
pleomorphic 
giant cell 
Radiation ERG 
Variable weak to 
strong 
Negative 
18 68 Adenosquamous ADT (short interval from diagnosis) ERG Positive 
Positive, slightly 
decreased 
intensity 
19 68 Pleomorphic No ERG Focal weak Focal A
cc
ep
te
d 
A
rt
ic
le
 This article is protected by copyright. All rights reserved 
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Table 3: Age, treatment history, and correlation of ERG molecular status with immunohistochemistry. 
*A low-grade prostatic adenocarcinoma was positive for ERG fluorescence in situ hybridization, but the 
sarcomatoid component was negative, interpreted as two unrelated tumor clones. **Specific treatment 
information was not available but the variant was diagnosed 2 years after biopsy diagnosis, suggesting 
likely interval treatment. In 2 patients with treatment history, the variant was found only a short time 
after initiating androgen deprivation therapy, suggesting that progression was not a typical therapy-
related event. Shaded fields = marked decrease in ERG staining in the variant. IHC = 
immunohistochemistry. ADT = androgen deprivation therapy.  
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